{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T12:49:15Z","timestamp":1782218955672,"version":"3.54.5"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Science and Technology Project of Tianjin Municipal Health Commission","award":["no. ZC20169"],"award-info":[{"award-number":["no. ZC20169"]}]},{"name":"Tianjin Key Medical Discipline (Specialty) Construction Project","award":["no. TJYXZDXK-010A"],"award-info":[{"award-number":["no. TJYXZDXK-010A"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>To evaluate the efficacy and safety of aumolertinib combined with pemetrexed and carboplatin as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation (exon 19 deletion or exon 21 L858R).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In phase II trial (NCT04646824), patients received aumolertinib 110 mg once daily plus pemetrexed (500 mg\/m2) and carboplatin (area under curve\u2005=\u20055) once every 3 weeks for 4 cycles, followed by maintenance aumolertinib (110 mg once daily) and pemetrexed (500 mg\/m2 once every 4 weeks). The primary endpoint was progression-free survival (PFS). Secondary endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>From November 2020 to October 2021, 34 patients were included for analysis. The median PFS was 28.0 months (95% CI, 18.7-36.9). The ORR was 91.2% (31\/34), and the DCR was 100%. The median OS was not reached. Of 28 patients with circulating tumor DNA (ctDNA) testing, 22 (78.6%) showed clearance of EGFR mutation after 2 or 4 cycles. The median PFS was 31 months in patients with EGFR mutation clearance in ctDNA, and the ORR of them was higher than those without EGFR mutation clearance in ctDNA (90.9% vs 33.3%). The most common grade\u2005\u2265\u20053 treatment-related adverse event was decreased neutrophil count (22 [64.7%]).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Aumolertinib plus chemotherapy shows potential as first-line treatment for patients with EGFR-mutant advanced NSCLC, which deserves to be investigated in randomized controlled trials. CtDNA clearance may be a prognostic marker.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae336","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T12:43:41Z","timestamp":1742042621000},"source":"Crossref","is-referenced-by-count":5,"title":["Aumolertinib plus chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 19 deletion or exon 21 L858R: a phase II trial"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3828-9754","authenticated-orcid":false,"given":"Yanwei","family":"Li","sequence":"first","affiliation":[{"name":"Department of Integrated Traditional and Western Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer , Tianjin, People\u2019s","place":["Republic of China"]},{"name":"Academy of Medical Engineering and Translational Medicine, Tianjin University , Tianjin 300192 ,","place":["People\u2019s Republic of China"]},{"name":"Tianjin\u2019s Clinical Research Center for Cancer , Tianjin ,","place":["People\u2019s Republic of China"]},{"name":"Key Laboratory of Cancer Prevention and Therapy , Tianjin ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenguang","family":"Li","sequence":"additional","affiliation":[{"name":"Academy of Medical Engineering and Translational Medicine, Tianjin University , Tianjin 300192 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoliang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Academy of Medical Engineering and Translational Medicine, Tianjin University , Tianjin 300192 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Li","sequence":"additional","affiliation":[{"name":"Academy of Medical Engineering and Translational Medicine, Tianjin University , Tianjin 300192 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"He","sequence":"additional","affiliation":[{"name":"Department of Integrated Traditional and Western Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer , Tianjin, People\u2019s","place":["Republic of China"]},{"name":"Tianjin\u2019s Clinical Research Center for Cancer , Tianjin ,","place":["People\u2019s Republic of China"]},{"name":"Key Laboratory of Cancer Prevention and Therapy , Tianjin ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanyu","family":"Pan","sequence":"additional","affiliation":[{"name":"Academy of Medical Engineering and Translational Medicine, Tianjin University , Tianjin 300192 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,15]]},"reference":[{"key":"2025031512432742200_CIT0001","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin."},{"key":"2025031512432742200_CIT0002","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1093\/annonc\/mdt205","article-title":"Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutmap)","volume":"24","author":"Dearden","year":"2013","journal-title":"Ann Oncol."},{"key":"2025031512432742200_CIT0003","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated egfr-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med."},{"key":"2025031512432742200_CIT0004","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","article-title":"Third-generation egfr and alk inhibitors: mechanisms of resistance and management","volume":"19","author":"Cooper","year":"2022","journal-title":"Nat Rev Clin Oncol."},{"key":"2025031512432742200_CIT0005","doi-asserted-by":"publisher","first-page":"102557","DOI":"10.1016\/j.ctrv.2023.102557","article-title":"Acquired resistance mechanisms to osimertinib: the constant battle","volume":"116","author":"Zalaquett","year":"2023","journal-title":"Cancer Treat Rev."},{"key":"2025031512432742200_CIT0006","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1200\/JCO.19.01154","article-title":"Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer","volume":"38","author":"Noronha","year":"2020","journal-title":"J Clin Oncol."},{"key":"2025031512432742200_CIT0007","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1200\/JCO.19.01488","article-title":"Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: Nej009 study","volume":"38","author":"Hosomi","year":"2020","journal-title":"J Clin Oncol."},{"key":"2025031512432742200_CIT0008","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced nsclc","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med."},{"key":"2025031512432742200_CIT0009","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1200\/JCO.21.02641","article-title":"Aeneas: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastaticnon-small-cell lung cancer with EGFR exon 19 deletion or l858r mutations","volume":"40","author":"Lu","year":"2022","journal-title":"J Clin Oncol."},{"key":"2025031512432742200_CIT0010","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised recist guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer."},{"key":"2025031512432742200_CIT0011","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The european organization for research and treatment of cancer qlq-c30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst."},{"key":"2025031512432742200_CIT0012","doi-asserted-by":"crossref","first-page":"e20671","DOI":"10.1200\/JCO.2019.37.15_suppl.e20671","article-title":"Therapeutic efficacy comparison of six major EGFR-TKIS in non-small-cell lung cancer patients with an activating EGFR mutation: a network meta-analysis","volume":"37","author":"Wu","year":"2019","journal-title":"J Clin Oncol."},{"key":"2025031512432742200_CIT0013","doi-asserted-by":"publisher","first-page":"100271","DOI":"10.1016\/j.esmoop.2021.100271","article-title":"Osimertinib plus platinum-pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced\/metastatic non-small-cell lung cancer: safety run-in results from the flaura2 study","volume":"6","author":"Planchard","year":"2021","journal-title":"ESMO Open"},{"key":"2025031512432742200_CIT0014","doi-asserted-by":"publisher","first-page":"6450","DOI":"10.1038\/s41467-021-26806-7","article-title":"Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes","volume":"12","author":"Liu","year":"2021","journal-title":"Nat Commun."},{"key":"2025031512432742200_CIT0015","doi-asserted-by":"publisher","first-page":"663581","DOI":"10.3389\/fpubh.2021.663581","article-title":"Clinical efficacy of infantile massage in the treatment of infant functional constipation: a meta-analysis","volume":"9","author":"Liu","year":"2021","journal-title":"Front Public Health."},{"key":"2025031512432742200_CIT0016","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.lungcan.2019.12.016","article-title":"Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer","volume":"141","author":"Ebert","year":"2020","journal-title":"Lung Cancer."},{"key":"2025031512432742200_CIT0017","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.lungcan.2021.11.010","article-title":"Incorporating circulating tumor DNA detection to radiographic assessment for treatment response in advanced egfr-mutant lung cancer","volume":"163","author":"Kok","year":"2022","journal-title":"Lung Cancer."},{"key":"2025031512432742200_CIT0018","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/S2213-2600(23)00135-2","article-title":"Sintilimab plus chemotherapy for patients with egfr-mutated non-squamous non-small-cell lung cancer with disease progression after egfr tyrosine-kinase inhibitor therapy (orient-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"11","author":"Lu","year":"2023","journal-title":"Lancet Respir Med."},{"key":"2025031512432742200_CIT0019","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1200\/JCO.23.01891","article-title":"Phase III, randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR- or ALK-rearranged or translocated non\u2013small-cell lung cancer (ATTLAS, KCSG-lu19-04)","volume":"42","author":"Park","year":"2024","journal-title":"J Clin Oncol."},{"key":"2025031512432742200_CIT0020","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/S1470-2045(22)00382-5","article-title":"Sintilimab plus bevacizumab biosimilar ibi305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (orient-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial","volume":"23","author":"Lu","year":"2022","journal-title":"Lancet Oncol."},{"key":"2025031512432742200_CIT0021","doi-asserted-by":"crossref","first-page":"LBA9000","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA9000","article-title":"Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous nsclc: phase 3 keynote-789 study","volume":"41","author":"Yang","year":"2023","journal-title":"J Clin Oncol."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/3\/oyae336\/62417514\/oyae336.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/3\/oyae336\/62417514\/oyae336.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T12:43:48Z","timestamp":1742042628000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyae336\/8078954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,10]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae336","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,3]]},"article-number":"oyae336"}}